Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HG146 capsules in recurrent or metastatic adenoid cystic carcinoma
CTR20244549Phase 2Active
- Sponsor
- HitGen
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HG146 in adenoid cystic carcinoma (ACC), sponsored by HitGen. Primary endpoints: Objective response rate and 6-month progression-free survival rate. Started Dec 2024; status: active.
02
Drugs
HG146
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on CTR20244549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244549.